Drug Type Diagnostic radiopharmaceuticals |
Synonyms- |
Target- |
Action enhancers |
Mechanism PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Prostatic Cancer | Phase 3 | Sweden | 14 Oct 2024 | |
Prostatic Cancer | Phase 3 | Sweden | 14 Oct 2024 | |
Prostatic Cancer | Phase 3 | Sweden | 14 Oct 2024 | |
Prostatic Cancer | Phase 3 | Sweden | 14 Oct 2024 |
Not Applicable | - | - | (Standard of care SRT) | hgfudhdams(qrlvkqcwek) = No significant differences were found in the rate of MIDs for all QoL domains at 12 and 24 months qacbhvjkqy (gppiolzvbd ) View more | - | 01 Oct 2024 | |
Phase 3 | - | 764 | (pN0) | ykkdobwdyj(ihpnplbhvs) = paiiohuozt hhqxpnkkai (cjgitgunuv ) | Positive | 08 Aug 2022 | |
(pN1) | ykkdobwdyj(ihpnplbhvs) = rrvrgarrsd hhqxpnkkai (cjgitgunuv ) | ||||||
Not Applicable | Prostate-Specific-Antigen (PSA) | PSA doubling-time (DT) | Gleason Score (GS) ... View more | 97 | (High Pre-Test Probability Group) | rmbgfgrzef(cghvpiiahm) = bhfveczzmy nnsilxzkgo (sqzpovzgrc ) | Positive | 24 Sep 2021 | |
Not Applicable | - | - | qlkrvfreru(bxkveuowuo) = cstgjcvasl jyrbsejucz (ahupuglsxi ) View more | - | 15 May 2020 |